glp 1 oral tablets FDA Approved: Orforglipron (Foundayo) — GLP-1 Drug • FDA approved for chronic weight management • Indicated for obesity and overweight with comorbidities • Oral, once-daily GLP-1 receptor agonist • First non-peptide The Quest for Oral GLP-1s

The GLP-1 Receptor Agonist Market is expected to witness significant expansion as pharmaceutical innovators continue to redefine the future of metabolic healthcare through next-generation GLP-1 therapies

A 2022 JAMA study on 338 adults who had overweight or obesity found that taking semaglutide and liraglutide, respectively, led to an average 15.8% and 6.4% loss in body weight over 68 weeks

Related reading 4 mm vs 5 mm vs 6 mm Pen Needles for GLP-1 Injections: What the Evidence Says 4 mm is the modern default for GLP-1 self-injection

A primary concern for menopausal GLP-1 users is the potential for accelerated bone thinning and muscle loss, which is why experts emphasize the necessity of a high protein intake and consistent strength training to mitigate these risks

The effects of GLP-1 agonists on musculoskeletal health and orthopedic care